Group 1: Market Impact - Trump's new tariff measures have negatively impacted global stock markets, with European markets collectively dropping over 1% [2][5] - The average tariff level on global goods has increased, raising concerns about potential economic growth slowdown and inflation, overshadowing previous optimism in large tech stocks driven by AI [5][7] Group 2: Economic Analysis - Analysts indicate that a 15% tariff rate is a poor agreement for the EU, with Goldman Sachs projecting a GDP loss of approximately 0.4 percentage points for the Eurozone by the end of 2026 [4] - The agreement signifies a turning point in US-EU relations, potentially affecting trade dynamics for years to come, ending an 80-year trend of reducing transatlantic trade barriers [4] Group 3: Regional Market Performance - Asian markets also experienced collective declines, with specific indices such as the KOSPI200 down by 4.08% and the Hang Seng Index down by 0.95% [8][9][7] - A-shares saw slight declines, with the Shanghai Composite Index down by 0.37% and the Shenzhen Component down by 0.17% [9] Group 4: Sector Performance - The pharmaceutical sector showed strength, with multiple stocks hitting the daily limit up, including Weikang Pharmaceutical up by 20% [14] - The photovoltaic sector rebounded, with stocks like Jiejia Weichuang and Shuangliang Energy hitting the daily limit up [15] Group 5: Company-Specific Developments - InnoScience's stock surged over 60% after being listed as a partner on NVIDIA's website, although the collaboration is still in the testing phase without substantial orders yet [17] - InnoScience's stock closed at HK$59.15, reflecting a 34.43% increase, with a trading volume of 64.21 million shares [18]

通过天眼查大数据分析，浙江新和成股份有限公司共对外投资了23家企业，参与招投标项目675次，知 识产权方面有商标信息366条，专利信息726条，此外企业还拥有行政许可110个。 新和成最新一期业绩显示，截至2025一季报，公司营业总收入54.40亿元、同比增长20.91%，归属净利 润18.80亿元，同比增长116.18%，扣非净利润18.80亿元，同比增长119.22%，流动比率2.610、速动比率 1.988、资产负债率29.74%。 金融界消息 截至2025年8月1日收盘，新 和 成（002001）报收于22.25元，下跌0.67%，换手率1.01%， 成交量30.65万手，成交金额6.90亿元。 天眼查商业履历信息显示，浙江新和成股份有限公司，成立于1999年，位于绍兴市，是一家以从事医药 制造业为主的企业。企业注册资本307342.168万人民币，实缴资本307342.168万人民币。公司法定代表 人为胡柏藩。 资金流向方面，今日主力资金净流入6417.59万元，占比成交额9.31%。其中，超大单净流入3721.99万 元、占成交额5.4%，大单净流入2695.59万元、占成交额3.91%，中单净流 ...

8月1日，Wind数据显示，A股市场共计49只个股涨停。其中燃气股胜通能源收获3连板；医药板块多股 连板，奇正藏药3连板，贵州百灵、昂利康、汉商集团2连板。一图速览今日连板股>> 连板股追踪丨A股今日共49只个股涨停 医药板块多股连板 ...

Group 1: Utilities - Recommended stock: Su Yan Jing Shen (603299.SH) due to its stable cash flow from traditional salt and salt chemical businesses, and the potential growth from gas storage projects [3][4] - The company is expected to enter a performance release period with the first phase of the gas storage project nearing production [4] Group 2: Pharmaceuticals - Recommended stock: Ang Li Kang (002940.SZ) as the impact of centralized procurement is gradually clearing, and new products are expected to drive revenue growth [4] - The introduction of ALK-N001, a promising anti-tumor candidate, is anticipated to enhance the company's innovation capabilities [4] Group 3: Media - Recommended stock: Alibaba-W (09988.HK) with a focus on the stabilization of traditional e-commerce and the potential for growth in the instant retail sector [5] - Alibaba Cloud's leading position in the domestic market and continuous revenue growth are highlighted [5] Group 4: Electronics - Recommended stock: Zhong Wei Company (688012.SH) due to its robust order backlog and continuous revenue growth driven by new product launches [6] Group 5: Non-Banking Financials - Recommended stock: China Life (601628.SH) for its excellent asset-liability matching and early transformation in dividend insurance sales [8] - The company is expected to release significant solvency capacity following asset reclassification [8] Group 6: Automotive - Recommended stock: Li Auto (02015.HK) as the company is positioned to leverage its strategic foresight and adaptability in the evolving automotive landscape [9] - The i-series is expected to maintain strong sales momentum, with the first model projected to achieve over 5,000 monthly sales [9] Group 7: Transportation - Recommended stock: YTO Express (600233.SH) with a leading growth rate in business volume, benefiting from the "anti-involution" trend in the industry [10] Group 8: Agriculture - Recommended stock: De Kang Agriculture (02419.HK) as it is positioned at a pivotal point in the agricultural sector, leveraging technology and innovative models for growth [12] - The company's platform strategy is expected to extend into other agricultural segments, enhancing its market presence [12] Group 9: Metals and New Materials - Recommended stock: Luoyang Molybdenum (603993.SH) with a strong performance in the first quarter, exceeding expectations [14] Group 10: North Exchange - Recommended stock: Yuan Hang Precision (833914.BJ) as a leading player in the domestic nickel-based conductor materials sector, benefiting from stable demand across multiple industries [14][15]

Core Viewpoint - The valuation of Nohow Health has been significantly reduced by multiple public funds, with Dachen Fund recently announcing a valuation of HKD 0.55 per share, marking the lowest valuation to date [1][3]. Valuation Adjustments - Dachen Fund's valuation of Nohow Health has been adjusted multiple times since its suspension in March 2024, dropping from HKD 14.14 per share to HKD 0.55 per share, representing a decline of over 96% [3][5]. - Other public funds, including Baoying, Penghua, and Bosera, have also reduced their valuations of Nohow Health, with Bosera maintaining a valuation of HKD 3.33 per share, which is still above HKD 2 per share [3][6]. Market Context - Nohow Health was once a leading stock in the Hong Kong market for cancer screening, with a market capitalization exceeding HKD 40 billion [5]. - The company has faced scrutiny over financial fraud allegations, leading to its suspension and inability to disclose timely financial reports [5][6]. Fund Management Perspective - The adjustments in valuation by fund managers aim to ensure the fairness and accuracy of fund net values, protecting investor interests [4][5]. - Continuous downward adjustments reflect a pessimistic outlook on Nohow Health's prospects for resumption of trading and heightened market vigilance regarding potential risks [6].

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board 100 Index decreased by 0.24% as of August 1, 2025, with mixed performance among constituent stocks [1] - Out of the constituent stocks, Aotewi led the gains with an increase of 7.18%, while Yuanjie Technology experienced the largest decline at 6.20% [1] - The Huaxia Sci-Tech 100 ETF (588800) saw a slight decrease of 0.28%, with a latest price of 1.06 yuan, but had a cumulative increase of 1.53% over the past week [1] Group 2 - The National Healthcare Security Administration (NHSA) has introduced a new pricing mechanism for newly listed drugs to support innovation in pharmaceuticals and medical devices, adding over 100 pricing items related to new medical technologies [1] - The NHSA aims to streamline the pricing and reimbursement process for new technologies and products, facilitating quicker returns on investment for clinically urgent innovations [1] - According to Zhongyin Securities, the national drug procurement has conducted 10 batches covering 435 types of drugs, with previous procurement methods focusing on "price for volume," which negatively impacted profitability and quality for some companies [2]

Macro Insights - July manufacturing PMI decreased by 0.4 percentage points to 49.3%, influenced by adverse weather conditions [6][8] - Manufacturing prices have begun to stabilize and rise due to ongoing capacity governance policies [8] - There is a need to further expand domestic demand, particularly in investment [8] Political Meeting Insights - The July Politburo meeting emphasized improving policy quality and effectiveness for the second half of the year [10][11] - The meeting highlighted the importance of consumer demand and stabilizing livelihoods, suggesting a focus on demand-side policies [13] - Policies to combat "involution" and promote collaboration between government and enterprises were also discussed [12] Fixed Income Insights - The July PMI data indicates a supply-demand decline, with the price index continuing to rise [16][18] - The manufacturing PMI remains below the expansion threshold for four consecutive months, reflecting weak seasonal performance [17] - The bond market is expected to enter a narrow fluctuation phase, with limited incremental policies [20] Computer Industry Insights - The AI application continues to progress, with significant growth in overseas tech giants driven by AI [22][25] - Domestic AI applications are expected to see increased monetization as models improve [25] - Key investment targets include companies like Kingdee International and Yonyou Network in the domestic AI application space [25] Pharmaceutical Industry Insights - Guobang Pharmaceutical reported a revenue of 3.026 billion yuan in the first half of 2025, a 4.63% increase [31] - The animal health segment saw a significant revenue increase of 53.5%, driven by strong sales of core products [32] - The company is expanding into new areas such as plant protection and health products, indicating a long-term growth strategy [32] Market Strategy Insights - The report suggests focusing on innovative drugs, AI hardware, and military-related themes for investment opportunities [36] - The macro policy environment is expected to support long-term investments in specialized and innovative enterprises [36] - Investors are advised to look for structural opportunities in growth-oriented companies with core technological advantages [36]

Group 1 - The pharmaceutical sector experienced a significant surge on August 1, with multiple stocks hitting the daily limit up, including Zhongsheng Pharmaceutical, Lianhuan Pharmaceutical, and Hanchang Group [1] - Yuekang Pharmaceutical saw an increase of over 12%, while Weikang Pharmaceutical rose by more than 9% [1]

Group 1 - The core focus of the article highlights the volatility in the stock market, particularly with AI stocks and the contrasting actions of institutional investors and retail investors [1] - The AI stock "Yidian Tianxia" saw a significant surge, with a 20% limit up and a 37.61% turnover rate, attracting 3.75 billion in buying from various investors [3] - Institutional investors are actively trading in "Xizang Tianlu," showing a back-and-forth dynamic with net selling and buying, indicating speculative trading based on policy expectations [3] Group 2 - Nord Shares, a player in solid-state battery technology, experienced a surge with foreign capital heavily investing, indicating confidence in high-end manufacturing and domestic substitution [4] - The article notes a significant retreat from retail investors in the pharmaceutical sector, with major sell-offs in stocks like "Yatai Pharmaceutical" and "Dezhan Health" [4][5] - The article advises caution for retail investors, suggesting they should be quick to act on trends like AI and high-end manufacturing while avoiding speculative plays in policy-driven stocks [6]

北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于上海毕得医药科技股份有限公司 法律意见书 国枫律股字[2025] A0378 号 致：上海毕得医药科技股份有限公司（贵公司） 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席并见 证贵公司 2025 年年度股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称 "《股东会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证 券法律业务管理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简 称"《证券法律业务执业规则》"）等相关法律、行政法规、规章、规范性文件及《上 海毕得医药科技股份有限公司章程》（以下简称"《公司章程》"）的规定，就本次会 议的召集与召开程序、召集人资格、出席会议人员资格、会议表决程序及表决结果等事 宜，出具本法律意见书。 网络投票结 ...